trial
as of 2026-07-01Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
NCTId NCT00419146
at a glance
Phase 2, Phase 3 · Completed
Enrollment 99 (actual)
Sponsored by University Hospital, Aker
Primary completion 2004-04
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2, Phase 3
Status
Completed
Enrollment
99 (actual)
Study type
Interventional
Allocation
Randomized
Model
Factorial
Masking
Quadruple
Start
2001-09
Primary completion
2004-04
Eligibility
ALL · 18 Years · 40 Years
Interventions & indications
Sponsors
University Hospital, AkerLead Sponsor
Diakonhjemmet HospitalCollaborator
Stanley Medical Research InstituteCollaborator
Laxdale LtdCollaborator
Scandinavian Society for PsychopharmacologyCollaborator
Shipowner Emil Stray's legacyCollaborator
Johanne and Einar Eilertsen's research fundCollaborator
AstraZenecaCollaborator
Solveig and Johan P. Sommer's foundationCollaborator
Josef and Haldis Andresen's legacyCollaborator
University of OsloCollaborator
Norwegian University of Science and TechnologyCollaborator
Investigators
2
Håvard Bentsen, MD PhDStudy Director
Odd Lingjærde, MD PhDStudy Chair
Sites
1 total
Oslo, Norway
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
99
Phase
PHASE2,PHASE3
Primary Completion Date
2004-04
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
collaborator
company
indication
investigator
person
person